Cabotegravir Suppliers & Bulk Manufacturers

Available Forms: Injection/ Tablet

Available Strengths: 600 mg/3 mL, 30 mg

Reference Brands: Apretude (USA), Vocabria (USA), Cabenuva (India)

Category: Critical Care

Cabotegravir is a long-acting antiretroviral medication used for HIV-1 prevention (PrEP) and treatment. It works by inhibiting the HIV integrase enzyme, preventing viral replication. Available as oral tablets (Vocabria) for lead-in and intramuscular injections (Apretude, Cabenuva, Rekambys) for maintenance or PrEP, it provides sustained HIV protection or therapy. Cabotegravir is available in Injection/ Tablet and strengths such as 600 mg/3 mL, 30 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Cabotegravir is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Cabotegravir can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Cabotegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. It is available as both an oral tablet (Vocabria) and a long-acting injectable formulation (Cabenuva, in combination with rilpivirine). Upon intramuscular gluteal administration, cabotegravir binds to the active site of HIV integrase, inhibiting the enzyme’s activity and preventing the integration of HIV-1 DNA into the host genome—a critical step in viral replication. By blocking integrase, cabotegravir effectively reduces the ability of HIV to establish infection, offering strong prophylactic and therapeutic potential. The long-acting injectable form allows for monthly or bi-monthly dosing, providing convenience and improved adherence compared to daily oral therapy. Cabotegravir has been evaluated in multiple clinical trials and has demonstrated efficacy in preventing HIV infection in high-risk populations as well as in maintaining viral suppression in people living with HIV when used with rilpivirine. Its safety, tolerability, and pharmacokinetic profile make it a promising option for HIV prevention and treatment strategies worldwide.